Our laboratory research interests focus on the pre-clinical development of cross complimentary approaches to integrate systemic therapies with radiotherapy through 1) elucidation of DNA damage response pathways 2) identification and characterization of novel radiosensitizers 3) development of tumor targeted approaches to improve the therapeutic ratio of radiotherapy. In contrast to current radiosensitization approaches, our strategies are biomarker driven and histologically agnostic. The overarching goal of our laboratory is to provide the preclinical rationale for translation to clinical trials of unique targeted systemic therapies in combination with radiotherapy.